Drug intelligence / Profile preview

NXC-301

Development stage: Preclinical
Lead developer: Nexcella
Modality: Cell Therapies
Administration: Intravenous

Overview

NXC-301 is a preclinical-stage cell therapy being developed by Nexcella, a subsidiary of Immix Biopharma. The program is currently being evaluated for the treatment of various B-cell malignancies, including Acute Lymphoblastic Leukemia (ALL), Large B-Cell Lymphoma (LBCL), and Mantle Cell Lymphoma (MCL). As of early 2024, Nexcella has not publicly disclosed the specific molecular target or the detailed mechanism of action for NXC-301, though it is part of the company's broader effort to develop next-generation cellular immunotherapies for hematologic cancers.

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on NXC-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NXC-301.

Explore the full profile